![The sights of Paris Air Show Day 1 [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/IMG_1798-scaled-e1750092780492.jpg?#)
AstraZeneca touts early Ultomiris survival data in children living with rare post-transplant complication
In initial results from a phase 3 trial, Ultomiris helped pediatric patients with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) achieve an overall survival rate of 87.2% at 26 weeks, AstraZeneca said. The data could help position Ultomiris to help address a potentially deadly post-transplant complication with no targeted treatment options.
In initial results from a phase 3 trial, Ultomiris helped pediatric patients with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) achieve an overall survival rate of 87.2% at 26 weeks, AstraZeneca said. The data could help position Ultomiris to help address a potentially deadly post-transplant complication with no targeted treatment options.
